Coherus BioSciences, Inc. is a pharmaceutical company based in the United States. With an ESG score of 28.1, the company is assessed as having a medium risk. They specialize in developing and commercializing FDA-approved oncology products, such as LOQTORZI and biosimilars like UDENYCA. Coherus BioSciences is focused on building an immuno-oncology franchise while generating revenue from their diversified portfolio of therapeutics.